Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

被引：6
|
作者：
Lin, Hung-Yao [1 ]
Tseng, Tai-Chung [1 ,2 ,3 ]
机构：
[1] Natl Taiwan Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Med Res, 1 Chang Te St, Taipei 10002, Taiwan
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2022年 / 28卷 / 02期
关键词：
Tenofovir disoproxil fumarate; Tenofovir alafenamide; Hyperlipidemias; Tenofovir;
D O I：
10.3350/cmh.2022.0028
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：181 / 182
页数：2
相关论文
共 50 条
  • [21] Response to letter to editor for risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
    Park, Jin Wook
    Yoo, Jeong-Ju
    Kim, Sang Gyune
    Kim, Young Seok
    HEPATOLOGY INTERNATIONAL, 2024, 18 (02) : 700 - 701
  • [22] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE IN THE TREATMENT OF DECOMPENSATED CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS B
    Deng, You
    Zhang, Shuqian
    Chen, Wenya
    Li, Jiashuo
    Li, Mengqi
    Wang, Qi
    Zhao, Hong
    Qiao, Bing
    Xie, Wen
    HEPATOLOGY, 2023, 78 : S517 - S518
  • [23] Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B
    Cao, Fei
    Fan, Tao
    Jiang, Xue
    Wang, Jian
    Liu, Yilin
    Zhu, Li
    Xiong, Ye
    Zhang, Shaoqiu
    Zhang, Zhiyi
    Pan, Yifan
    Li, Yuanyuan
    Jiang, Chao
    Xia, Juan
    Yan, Xiaomin
    Li, Jie
    Liu, Xingxiang
    Zhu, Chuanwu
    Huang, Rui
    Wu, Chao
    VIROLOGY JOURNAL, 2024, 21 (01)
  • [24] CHANGES OF LIVER FIBROSIS AND STEATOSIS IN PATIENTS WITH CHRONIC HEPATITIS B RECEIVING TENOFOVIR ALAFENAMIDE
    Liang, Lilian Yan
    Wong, Vincent
    Yip, Terry Cheuk-Fung
    Tse, Yee-Kit
    Hui, Vicki Wing Ki
    Wong, Grace L. H.
    HEPATOLOGY, 2021, 74 : 471A - 472A
  • [25] Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients
    Sun, Yu-Tong
    Chen, Qian-Qian
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (01) : 109 - 111
  • [26] Investigation of Efficacy and Safety in Chronic Hepatitis B Patients Receiving Tenofovir Alafenamide Treatment
    Kahveci, Huseyin Nadir
    Yildiz, Orhan
    Karabulut, Kaan
    Ture, Zeynep
    Unuvar, Gamze Kalin
    Aygen, Bilgehan
    JOURNAL OF CLINICAL PRACTICE AND RESEARCH, 2024, 46 (04):
  • [27] Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection
    Buti, Maria
    Riveiro-Barciela, Mar
    Esteban, Rafael
    JOURNAL OF INFECTIOUS DISEASES, 2017, 216 : S792 - S796
  • [28] From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B
    Rodrigo, Minna
    Hartley, Christopher
    Wasuwanich, Paul
    Van, Trung
    Karnsakul, Wikrom
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (12) : 1099 - 1106
  • [29] Reply to correspondence on "Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide"
    Cheng, Pin-Nan
    Yu, Ming-Lung
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [30] Comparable risk of cardiovascular events in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
    Hong, Hyeyeon
    Choi, Jonggi
    Choi, Won-Mook
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    JOURNAL OF HEPATOLOGY, 2023, 78 : S1139 - S1139
12345